ATBPF - Antibe Therapeutics teams up with Dalriada Drug Discovery to accelerate pipeline expansion

Antibe Therapeutics (ATBPF) announces a strategic collaboration with Dalriada Drug Discovery to develop new drug candidates and bolster the company's intellectual property (“IP”) position for its current pipeline.Dalriada is a contract research organization (“CRO”) specializing in the development of small-molecule drugs from initial discovery to development candidate nomination and management of IND-enabling studies.Antibe also announces the appointment of Harvey Schipper to the company's scientific advisory board.Schipper is a practicing physician, and is also a professor of medicine and law at the University of Toronto.

For further details see:

Antibe Therapeutics teams up with Dalriada Drug Discovery to accelerate pipeline expansion